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ABSTRACT
The efficacy of direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C 
(CHC) in liver transplant recipients is poorly understood, and several factors, including 
immunosuppression, drug interactions, elevated viraemia, and intolerance to ribavirin 
(RBV), can reduce cure rates. We conducted a real-life study on liver transplant recipients 
with CHC treated with a combination of sofosbuvir (SOF) and daclatasvir (DCV) or 
simeprevir (SIM), with or without RBV, followed-up for 12 to 24 weeks. The treatment 
effectiveness was assessed by determining the sustained virological response (SVR) rates 
at 12 or 24 weeks after the treatment cessation. Eighty-four patients were evaluated, with a 
mean age of 63.4 ± 7.4 years, HCV genotype 1 being the most prevalent (63.1%). Nineteen 
patients (22.7%) had mild fibrosis (METAVIR < F2) and 41 (48.8%) significant fibrosis 
(METAVIR ≥ F2). The average time between liver transplantation and the start of treatment 
was 4 years (2.1-6.6 years). The SOF + DCV regimen was used in 58 patients (69%). RBV in 
combination with DAAs was used in seven patients (8.3%). SVR was achieved in 82 patients 
(97.6%), and few relevant adverse events could be attributed to DAA therapy, including a 
patient who stopped treatment due to a headache. There was a significant reduction in ALT, 
AST, GGT and FA levels, or the APRI index after 4 weeks of treatment, which remained 
until 12/24 weeks post-treatment. DAA treatment of CHC in liver-transplanted patients 
achieved a high SVR rate and resulted in the normalization of serum levels of liver enzymes. 
KEYWORDS: Chronic hepatitis C. Direct-acting antiviral. Liver transplant. Sofosbuvir. 
Effectiveness. Brazil. Liver transplant recipient. 
INTRODUCTION
The global prevalence of hepatitis C virus (HCV) infection is estimated at 1%, 
corresponding to 71.1 million viraemic subjects worldwide1,2. Chronic hepatitis 
C (CHC) was the third leading cause of liver transplantation in the United States 
of America (USA) in 2017, and over the last 15 years, it has accounted for 54% 
of indications for liver transplantation due to cirrhosis in Europe2. In Brazil, in 
2019, it has been estimated that 22,747 thousand people were infected with HCV3, 
with genotypes 1 and 3 being the most frequent4, and these genotypes are also 
predominant in Northeast Brazil5. Between 2000 and 2015, CHC accounted for 
more than 70% of the 46,314 deaths caused by viral hepatitis in Brazil6.
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A sustained virological response (SVR) is defined as 
undetectable HCV at 12 or more weeks after the end of 
treatment, which is associated with a reduction in serum 
levels of liver enzymes due to an improvement of the 
necro-inflammatory activity in the liver parenchyma, with 
subsequent reductions in the progression of liver fibrosis 
and mortality7. In patients with active CHC undergoing 
liver transplantation, recurrence of the infection in the 
transplanted liver is universal, with a negative impact on 
graft and patients’ survival3,7. In these patients, the viral 
load may be even higher than in non-transplanted patients7. 
Due to the high rate of graft reinfection and accelerated 
progression of the liver disease, liver fibrosis is observed 
in approximately 30% to 40% of transplanted patients 
with CHC, and progression to cirrhosis occurs within 
approximately five years8. Accordingly, recipients’ survival 
after liver transplantation are reduced in HCV-infected 
recipients compared to uninfected ones7.
For many years, interferon (IFN)-based antiviral 
therapies have been the main treatment option for CHC7. 
The first generation of direct acting antivirals (DAAs), 
boceprevir and telaprevir, has been used in combination 
with pegylated (PEG)-IFN and ribavirin (RBV)9. However, 
these therapeutic regimens have limited efficacy, and cause 
several side effects, in addition to achieving only low SVR 
rates in transplant recipients10. The first studies employing 
second-generation DAAs, such as sofosbuvir, a nucleotide 
analogue that inhibits the HCV polymerase, in combination 
with simeprevir, a protease inhibitor, or daclatasvir, an 
NS5A inhibitor, in the treatment of CHC in liver transplant 
recipients, revealed SVR rates of approximately 80%, 
which were still lower than the SVR rates observed in 
non-transplanted patients that exceeds 90%11,12.
As of 2015, the Brazilian Ministry of Health (MS) 
made CHC therapy available to patients in the Unified 
Health System (SUS), including sofosbuvir, combined 
with simeprevir or daclatasvir, with or without RBV13. 
Indication of treatment for transplant recipients was 
considered a priority, regardless of the stage of fibrosis13,14. 
Although DAAs have revolutionized the CHC therapy, 
some factors can reduce SVR rates in liver transplant 
recipients, including the presence of comorbidities, 
drug interactions and lower tolerance to RBV7,14. Based 
on previously published literature, there are reports 
on the treatment of HCV infections with DAAs in 
Brazil, reaching SVR rates between 92% and 95%15-18. 
However, only three studies included exclusively liver 
transplantrecipients, all in the South and Southeast 
regions of the country19-21. This study aimed to describe 
the SVR rates after treatment of patients with CHC 
having undergone liver transplantation and treatment with 
sofosbuvir and daclatasvir or simeprevir, with or without 
RBV, in a real life study in the Brazilian Northeast region.
MATERIALS AND METHODS
Study design and population
As part of this retrospective observational study, we 
included liver transplant recipients diagnosed with CHC, 
who had been treated with sofosbuvir and daclatasvir or 
simeprevir, with or without RBV. Patients were selected 
in two hepatology reference centers located in Northeast 
Brazil, from December 2015 to March 2019. For the 
recruitment, liver transplant recipients had to be aged 18 
years or older, undergone liver transplantation, diagnosed 
with CHC based on the presence of anti-HCV antibodies 
for more than six months, present with positive HCV RNA 
detected by quantitative PCR, and subjected to treatment 
with second-generation DAAs. Pregnant women and those 
subjects coinfected with the human immunodeficiency 
virus (HIV) or who received other organ transplants 
were excluded from the study. Patients were followed-
up until the assessment of SVR rates at 12 or 24 weeks 
after the end of treatment. During this period, interviews 
were conducted, and data were obtained from medical 
records using a standardized questionnaire for research 
purposes, which included demographic data and clinical 
characteristics. The variables studied were age, sex, viral 
load, HCV genotype, liver fibrosis staging (determined by 
liver biopsy or APRI and/or FIB4 scores), treatment status 
(naive or treated), immunosuppressants in use, therapeutic 
regimen and duration and response to treatment with DAAs. 
All clinical data of the patients were recorded in a research 
database. All individuals used immunosuppressive therapy: 
tacrolimus and/or mycophenolate sodium or mofetil 
and/or prednisone and/or sirolimus.
This study was approved by the Research Ethics 
Committee of the Health Sciences Center of the Federal 
University of Pernambuco (CCS-UFPE), Recife, Brazil, 
under the protocol Nº 2,383,189/2018. All patients who 
agreed to participate in the study signed a free and informed 
consent form (ICF).
Clinical and laboratory evaluations
Clinical evaluations and blood sampling for laboratory 
tests were carried out in the following periods: up to 
3 months before the start of treatment, at week 4 of treatment, 
at the end of treatment, and 12 or 24 weeks after the end of 
treatment.Biochemical and hematological analyses included 
assessment of haemoglobin (Hb), platelets count, aspartate 
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aminotransferase (AST), alanine aminotransferase (ALT), 
gamma-glutamyl transferase (GGT), alkaline phosphatase 
(ALP), bilirubin (Bt), creatinine (Cr) and albumin levels. 
All analyses were performed in the laboratories of the two 
reference centers, and laboratory data were collected from 
medical records.
Quantification of HCV RNA
Quantification of HCV RNA was performed at the 
Central Laboratory of Pernambuco (LACEN-PE) using 
real-time PCR (qPCR) (Abbott Diagnostics®, Chigago, 
IL, USA), with a quantification range of 12 to 108 IU/mL, 
using the m2000 Real-Time System (Abbott®, Chicago, IL, 
USA)22. The 5’ untranslated region (UTR) was used as a 
target for detection of HCV load23.
HCV RNA was quantified up to 3 months before the start 
of treatment, at week 4 of treatment, at the end of treatment, 
and at week 12 or 24 after the end of treatment to assess 
the SVR rate. SVR was defined as undetectable levels of 
HCV RNA at 12 or 24 weeks after the end of the antiviral 
therapy. Virological failure was defined as detectable HCV 
RNA at 12 or 24 weeks after the end of treatment.
Assessment of hepatic fibrosis
The stage of liver fibrosis was assessed by biopsy 
performed up to one year before starting the treatment 
or by serological indices APRI (based on the AST ratio 
and platelets count), and FIB-4 (based on age, AST and 
ALT levels, and platelets count) up to three months before 
starting the treatment24. To assess the extent of liver 
fibrosis through biopsy, the METAVIR scoring system was 
used (F0 = no fibrosis; F1 = mild fibrosis; F2 = moderate 
fibrosis; F3 = advanced fibrosis; F4 = cirrhosis)25. For the 
APRI score, the lower and upper cutoff points of 0.5 and 
1.50 were used to diagnose the absence and presence of 
significant fibrosis (METAVIR ≥ F2). For the FIB4 score, 
the lower and upper cut-off points of 1.45 and 3.35 were 
used to diagnose the absence and presence of advanced 
fibrosis (METAVIR ≥ F3)26.
CHC therapy
The treatment scheme for CHC, including time, dosage, 
and whether or not RBV should be used, followed the 
Clinical Protocol and Therapeutic Guidelines for Hepatitis 
C and Coinfections (PCDT) 2015/201913,27, provided by 
the Brazilian Ministry of Health, which is based on the 
viral genotype, previous experimentation with DAAs, and 
fibrosis stage, summarised as follows: 
-  genotype 1: sofosbuvir plus simeprevir or daclatasvir, 
with or without RBV;
-  genotype 2: sofosbuvir and RBV;
-  genotype 3: sofosbuvir and daclatasvir, with or without 
RBV.
All treatment regimens were administered for 12 or 
24 weeks. The addition of RBV was optional, especially 
when there were predictors of a worse virological response, 
such as cirrhosis or previous null response13,27. 
Statistical analysis
Regarding the descriptive analysis of the demographic 
and clinical data of the transplant recipients, the frequencies 
of qualitative variables, as well as the mean ± standard 
deviation or median (25th-75th percentile) of continuous 
variables were evaluated. The normal distribution of 
continuous variables was verified by applying the Shapiro-
Wilk normality test.
Differences between the different time points of serial 
evaluations of biochemical and hematological parameters 
and hepatic fibrosis staging (before the start of treatment, 
at week 4 and at the end of treatment, and after 12 or 
24 weeks after the end of treatment) were assessed using 
the paired t-test, whenever normality and homogeneity of 
variance testing allowed it, or the Wilcoxon signed-rank 
test for data with non-parametric distribution. Differences 
were considered statistically significant at a p < 0.05. The 
SPSS Statistics software, version 25 for Windows (IBM 
Corporation, Armonk, NY, USA) was used for statistical 
analyses.
RESULTS
Eighty-seven liver transplant recipients with CHC 
were evaluated between December 2015 and March 
2019. Of these, three (3.4%) were excluded: one due 
to HIV coinfection, and two for having a transplanted 
kidney. The clinical and demographic characteristics 
of the 84 patients included in this study are shown in 
Table 1. Male sex predominated (63.1%), and the mean 
age was 63.4 ± 7.4 years. Genotype 1 was observed in 
53 patients (63.1%). Diabetes mellitus and systemic arterial 
hypertension were the most frequent comorbidities, present 
in 48.9% and 52.3% of patients, respectively. Tacrolimus 
was used by 62 (74%) patients, either as single therapy or 
in combination with mycophenolate.
The median time between liver transplantation and 
start of the current treatment was 4 years (2.1-6.6 years). 
Among the 84 patients, 19 (22.7%) had mild fibrosis 
(METAVIR < F2), 41 (48.8%) had significant or moderate 
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fibrosis (METAVIR = F2), and 24 (28.5%) had advanced liver 
fibrosis and/or cirrhosis (METAVIR > F2). Hepatocellular 
carcinoma (HCC) was diagnosed in five patients (6.0%) 
before CHC treatment; another two patients (2.4%) were 
diagnosed with HCC after the end of the current treatment. 
Both had undergone liver transplantation more than five 
years ago, one of them had mild fibrosis (METAVIR < F2), 
and the other had advanced liver fibrosis/ cirrhosis 
(METAVIR F3-F4).
Table 2 describes the treatment regimens and responses 
to DAAs. Among the 84 patients, 41 (48.8%) had previously 
been treated with IFN or PEG-INF together with RBV, as 
follows: 12 (14.3%) with INF + RBV and 20 (23.8%) with 
PEG + RBV. Two patients (2.4%) were treated with first-
generation protease inhibitors, one with boceprevir and the 
other with telaprevir.
For the current treatment, combination therapy with 
SOF + DCV was the most frequent, which was used for 
treating 58 patients (69%), with RBV being administered in 
Table 1 - Demographic and clinical characteristics of 84 liver 
transplant recipients with chronic hepatitis C, treated with 
sofosbuvir associated with daclatasvir or simeprevir, Northeast 
- Brazil, 2015-2019. 




Age (years)* 63.4 (± 7.4)
Ethnicity, n (%)
White 28 (33.3)
Mixed (black and white) 52 (61.9)
Black 4 (4.8)






Diabetes mellitus 36 (42.9)
Systemic arterial hypertension 49 (58.3)




1 a 5 (6.0)
1 b 35 (41.7)
2 1 (1.2)
3 21 (25.0)
3 a 8 (9.5)
3 e 4 1 (1.2)
Immunosuppression
Tacrolimus 21 (25.0)
Mycophenolate sodium 6 (7.1)
Tacrolimus + Mycophenolate sodium 38 (45.2)
Tacrolimus + mycophenolate mofetil 3 (3.6)
Prednisona 
+ Mycophenolate sodium 5 (6.0)
Sirolimus + Mycophenolate sodium 11 (13.1)
†Mean ± standard deviation.
Table 2 - Characteristics of previous and the current treatment of 
CHC with sofosbuvir associated with daclatasvir or simeprevir, in 
84 liver transplant recipients with chronic hepatitis C, Northeast 
- Brazil, 2015-2019.
Characteristics (N=84)
Previous treatment, n (%)
Yes 41 (48.8)
No information 1 (1.2)




PEG IFN 4 (4.8)
PEG IFN+RBV 20 (23.8)
Boceprevir 1 (1.2)
Telaprevir 1 (1.2)
No information 1 (1.2)




No information 1 (1.2)





Treatment duration, n (%)
12 weeks 80 (95.2)
SVR, n (%) 82 (97.6)
†Mean ± standard deviation; IFN = interferon; Peg-IFN =  egylated 
interferon; DCV = daclatasvir ; SMV = simeprevir ; 
SOF = sofosbuvir; RBV = ribavirin; SVR = sustained virological 
response.
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six patients (7.1%). The SOF + SMV combination treatment 
was used in 19 patients (22.6%), with RBV administered 
to only one individual (1.2%). Among the 84 patients, 
SVR was achieved in 82 (97.6%). In 38 and 44 patients, 
HCV RNA screening was carried out 12 and 24 weeks 
after the end of treatment, respectively. The two patients 
for whom SVR was not achieved, did not complete the 
treatment with DAAs according to the proposed scheme, 
and were considered non-responders in the intention-
to-treat assessment. One of them used the SOF + SIM 
combination treatment for only four weeks with errors, and 
another patient developed headache during the first week 
of SOF + SIM treatment and, on his own, suspended the 
therapeutic regimen.
Adverse events were recorded in 18 (25%) patients: 
fatigue (n = 6 - 8.3%), headache (n = 5 - 6.9%), abdominal 
pain in 4 (n = 4 - 5.6%), dizziness (n = 3 - 4.2%), nausea 
(n = 2 - 2.8%), diarrhea (n = 2- 2.8%), depressive symptoms 
(n = 1 - 1.4%), spontaneous sweating (n = 1 - 1.4%) and 
skin lesions (n = 1 - 1.4%) . In only one of these patients, 
the treatment was suspended due to a headache related 
to the use of DAAs. No drug interaction was observed 
with any of the antiviral regimens used. Prior to the 
prescription of the antiviral regimen, an assessment was 
made regarding possible interactions, particularly with the 
immunosuppressants in use.
Serial assessment of biochemical and hematological 
parameters, as well as liver fibrosis staging is described 
in Table 3 and Figure 1. Hemoglobin levels and platelet 
counts in transplant recipients remained stable at 12 and 
24 weeks after the end of treatment. In addition, there was 
a significant reduction in the serum concentrations of ALT, 
AST, GGT and ALP at week 4, which was maintained up 
to 24 weeks after the treatment. The mean values of APRI 
and FIB-4 showed a significant reduction at week four of 
treatment, which was maintained until the end (Figure 2).
DISCUSSION
This real-life study describes the treatment of recurrent 
HCV infection after liver transplantation using DAAs in two 
public university hospitals in Northeast Brazil. It covers a 
specific population, for which the evolution of CHC is more 
aggressive, and whose treatment with IFN, even in the PEG 
formulation, presents a very low chance of SVR due to drug 
interactions, in addition to providing several side effects and 
difficulties in adjusting the doses of immunosuppressants.
This study included 84 liver transplant recipients with 
CHC, who were treated with second-generation DAAs, 
achieving a SVR of 97.6%. These data are similar to those 
observed in a French cohort, which evaluated treatment 
with SOF + CVD in 137 transplant patients with HCV 
recurrence, and showed a SVR rate of 96%, regardless of 
whether RBV was used28. Likewise, in the ALLY-1 study, 
which involved 53 liver transplant patients followed-up 
for 12 weeks and RVS12 was achieved in 95% and 91% of 
patients with genotypes 1 and 3, respectively29. The same 
was reported in a study by Gutierrez et al.30, who evaluated 
treatment regimens of SOF + SMV for 12 weeks, and found 
SVR in 93.4% of 57 liver transplant recipients with CHC30.
Three national studies have shown SVR rates between 
90% and 98% after treatment of liver-transplanted patients 
with CHC using DAAs19-21.The characteristics of the 
transplanted patients with CHC included in this study, i.e., 
associated predominantly with HCV genotype 1 and mild 
fibrosis, can justify the high SVR rates, very similar to those 
found by Araujo et al.20 and Zanaga et al.21. In fact, in a 
study carried out in Sao Paulo including 53 patients, 23% 
of which had mild fibrosis (F0-F1), while 43% presented 
with moderate fibrosis (F2), the SVR rate was 98%, with 
virological failure occurring only in one cirrhotic patient21. 
On the other hand, a study by Mucenic et al.19 used AEDs on 
39 liver-transplanted patients with CHC in Southern Brazil, 
with a predominance of HCV genotype 3, revealing a SVR 
rate of 90%, which was slightly lower than that described in 
our study and the other two Brazilian studies19. It is possible 
that the lower response rate was due to the predominance of 
genotype 3 two thirds of the cases), and more patients with 
advanced fibrosis (F4) being included. These two factors, 
genotype 3 and advanced fibrosis/cirrhosis are predictive 
of lower SVR in both transplanted and non-transplanted 
patients31,32.
When evaluating large samples, differences in SVR 
rates were observed according to the different genotypes. 
In a Brazilian study, including the largest survey in Latin 
America of patients with CHC treated with second-
generation DAAs, coordinated by the Brazilian Society of 
Hepatology (BSH), including 20 Brazilian States and 3,939 
patients, SVR rates were higher than 95% and about 90% 
in patients with genotypes 1 and 3, respectively, varying 
depending on the type of therapeutic scheme, sex, and the 
presence of decompensated cirrhosis33. The results presented 
in our study on transplanted patients with CHC are similar 
to those of the multicentre study of the BSH, possibly 
due to the very similar distribution of HCV genotypes, 
with a predominance of genotype 15,33. Additionally, a 
multicentre study on the efficacy of DAAs upon treatment 
of 123 transplanted patients with CHC conducted in three 
transplant centres in the USA demonstrated that the SVR 
rate was lower in those with advanced fibrosis (METAVIR 
F3-F4, 81%) compared to those with mild and moderate 
fibrosis (METAVIR F0-F2, 93 %)31. Similar results were 
Silva et al.
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reported in a systematic review involving 885 transplanted 
patients, all of the cases associated with genotype 1, with 
higher SVR rates (p < 0.01) in patients with METAVIR 
F0-F2 (SVR = 97%, 95% CI: 0.93-0.99), when compared 
to patients with F3-F4 (SVR = 85%, 95% CI: 0.79-0.90)32. 
It is worth noting that some studies, including a 
meta-analysis, have shown a significant reduction in 
liver fibrosis after treatment of CHC with DAAs, both 
through the evaluation of fibrosis by elastography and 
APRI and FIB-4 scores in non-transplanted patients34. 
These data indicate a reduction in the progression of 
CHC to cirrhosis and, consequently, in the number of 
cases requiring liver transplantation as a consequence of 
HCV infection. However, there are few studies evaluating 
fibrosis regression after treatment of CHC with DAAs in 
liver-transplanted patients35. Indeed, Omar et al. found a 
progressive improvement in the degree of liver fibrosis, 
as indicated by elastography and serum scores, 12 and 
18 months after the treatment of CHC with DAAs in 
52 liver transplant patients35. The regression APRI and 
FIB-4 scores after treatment of CHC with DAAs, in both 
liver transplant and non-transplant patients, can occur by 
reducing serum levels of liver enzymes or by increasing 
the number of platelets36. 
Figure 1 - Comparison of liver enzymes: ALP (UI/ L); GGT (UI/ L); ALT (UI/ L); AST (UI/ L), at different times: before treatment/
baseline (BA); week 4 of treatment (4W); end of treatment (EoT); week 12 post-treatment (PW12); and week 24 post-treatment 
(PW24) of 84 liver transplantrecipients with chronic hepatitis C, treated with sofosbuvir associated with daclatasvir or simeprevir. 
Comparisons made with Median and percentiles (P25-P75).
Figure 2 - APRI and FIB-4 values at different times: before treatment/ baseline (BA), week 4 of treatment (4W), end of treatment 
(EoT), week 12 post-treatment (PW12) and week 24 post-treatment (PW24) of 84 liver transplant recipients with chronic hepatitis 
C, treated with sofosbuvir associated with daclatasvir or simeprevir. (A) APRI. (B) FIB-4. Comparisons made with median and 
percentiles (P25-P75) with respect to baseline levels.
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Classically, patients with CHC have elevated serum 
levels of liver enzymes, reflecting virus-induced damage 
to hepatocytes, and normalization occurring during and 
after treatment, because of HCV elimination36. In fact, 
in our study, this expected behaviour of serum levels of 
liver enzymes was observed, starting at week 4 after the 
beginning of DAA therapy, reflecting a reduction in the necro-
inflammatory activity in the liver parenchyma accompanying 
the elimination of HCV. We have also observed a progressive 
reduction in APRI and FIB-4 scores at 12 and 24 weeks after 
the end of the DAA therapy. The decrease in these scores must 
have occurred due to a reduction in serum aminotransferase 
levels, and the fact that there was no significant increase in the 
number of platelets, during or after antiviral therapy. The low 
increase in the number of platelets in our study was possibly 
due to the absence of thrombocytopenia in our patients 
before starting the therapy with DAAs, as was also seen in 
the study by Omar et al.35. Accordingly, in a study by Hsu 
et al.36 in non-transplanted patients with CHC treated with 
DAAs, an increase in the number of platelets was observed 
only in patients who presented with thrombocytopenia before 
the treatment36.
Side effects of DAAs, mostly mild, occurred in a quarter 
of our patients, with fatigue (8.3%) and headache (6.9%) 
being the most frequent. In only one patient, treatment was 
suspended due to an adverse effect (headache), coinciding 
with the finding of other authors claimed that DAAs have 
few side effects, requiring interruption of therapy in less 
than 2% of patients19,37. The main adverse reactions reported 
are headache, insomnia, fatigue, nausea and diarrhoea38,39. 
In a real life study by Bernuth et al.40 including 37 liver 
transplanted patients with CHC treated with DAAs, few 
patients had anemia, which was related to the use of RBV. 
In only one patient, it was necessary to suspend the therapy 
due to the worsening of serum creatinine levels, which were 
already altered before the therapy with SOF + ledipasvir 
had started40. 
It is worth noting that the headache was the only cause 
of treatment interruption due to side effects in our study. 
The second case of failure resulted from a lack of adherence 
due to a lack of understanding of how to administer the 
therapeutic regimen. These two cases should be considered 
non-responders in the intention-to-treat assessment on 
the effectiveness of DAAs, although these patients did 
not complete the initial proposed therapy. These issues 
can occur in real life studies, and constitute limitations to 
treatment assistance, which can occur in medical practice. 
Certainly, these failures in adherence to treatment could 
have been circumvented in a prospective and controlled 
study, highlighting the importance of clarifications and 
monitoring of patients before and during therapy with 
DAAs. Other limitations of our study that are worth 
considering are the small number of patients involved 
and the short follow-up time after the end of the antiviral 
treatment. In conclusion, treatment with second-generation 
DAAs achieved high SVR rates in a real life study, and was 
well tolerated by liver-transplanted patients with HCV in 
the Northeast of Brazil. Future studies with larger sample 
sizes will be necessary to confirm these findings.
ACKNOWLEDGMENTS
We would like to thank the Liver Transplant Unit of the 
Oswaldo Cruz Hospital of the University of Pernambuco 
(UPE) and the Hepatology Service/ General Transplant 
Unit (UGT) of the Professor Fernando Figueira Institute of 
Integral Medicine (IMIP), where the study was carried out, 
and the development agency Fundação de Amparo à Ciencia 
e Tecnologia of the State of Pernambuco (FACEPE) - Brazil.
REFERENCES
 1.  Medeiros T, Salviato CM, Rosário NF, Saraiva GN, Esberard EB, 
Almeida JR, et al. Adverse effects of direct acting antiviral-
based regimens in chronic hepatitis C patients: a Brazilian 
experience. Int J Clin Pharm. 2017;39:1304-11. 
 2.  World Health Organization. Guidelines on hepatitis B and C 
testing. Geneva: WHO; 2017. 
 3.  Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Hepatites virais 2020. Bol Epidemiol. 2020;N. Esp:1-80.
 4.  Focaccia R, Baraldo DC, Ferraz ML, Martinelli AL, Carrilho FJ, 
Gonçales FL, et al. Demographic and anthropometrical analysis 
and genotype distribution of chronic hepatitis C patients treated 
in public and private reference centers in Brazil. Braz J Infect 
Dis. 2004;8:348-55. 
 5.  Alvarado-Mora MV, Moura IM, Botelho-Lima LS, Azevedo 
RS, Lopes E, Carrilho FJ, et al. Distribution and molecular 
characterization of hepatitis C virus (HCV) genotypes in 
patients with chronic infection from Pernambuco State, Brazil. 
Virus Res. 2012;169:8-12. 
 6.  Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de Vigilância, Prevenção e Controle das 
Infecções Sexualmente Transmissíveis, do HIV/Aids e das 
Hepatites Virais. Protocolo clínico e diretrizes terapêuticas 
para hepatite C e coinfecções. Brasília: Ministério da Saúde; 
2017.
 7.  European Association for the Study of the Liver. EASL 
recommendations on treatment of hepatitis C 2015. J Hepatol. 
2015;63:199-236. 
 8.  Berenguer M. Systematic review of the treatment of established 
recurrent hepatitis C with pegylated interferon in combination 
with ribavirin. J Hepatol. 2008;49:274-87. 
Rev Inst Med Trop São Paulo. 2021;63:e6
A real-life study on the impact of direct-acting antivirals in the treatment of chronic hepatitis C
Page 9 of 10
 9.  Butt AA, Kanwal F. Boceprevir and Telaprevir in the management 
of hepatitis C virus infected patients. 2012;54:96-104. 
 10.  European Association for the Study of the Liver. EASL 
recommendations on treatment of hepatitis C 2018. J Hepatol. 
2018;69:461-511. 
 11.  Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin 
P. Direct-acting antivirals for the treatment of hepatitis C virus 
infection: optimizing current IFN-free treatment and future 
perspectives. Liver Int. 2016;36 Suppl 1:47-57. 
 12.  Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, 
Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, 
with or without ribavirin, to treat chronic infection with 
hepatitis C virus genotype 1 in non-responders to pegylated 
interferon and ribavirin and treatment-naive patients: the 
COSMOS randomised study. Lancet. 2014;384:1756-65. 
 13.  Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. 
Departamento de DST, Aids e Hepatites Virais. Protocolo 
clínico e diretrizes terapêuticas para hepatite C e coinfecções. 
Brasília: Ministério da Saúde; 2015. 
 14.  Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, 
and challenges. Gastroenterology. 2014;146:1176-92. 
 15.  Ferreira VL, Borba HH, Wiens A, Pedroso ML, Radunz VF, 
Ivantes CA, et al. Effectiveness and tolerability of direct-acting 
antivirals for chronic hepatitis C patients in a Southern state 
of Brazil. Braz J Infect Dis. 2018;22:186-92. 
 16.  Holzmann I, Tovo CV, Minmé R, Leal MP, Kliemann MP, 
Ubirajara C, et al. Effectiveness of chronic hepatitis C treatment 
with direct-acting antivirals in the public health system in 
Brazil. Braz J Infect Dis. 2018;22:317-22. 
 17.  Costa VD, Delvaux N, Brandão-Mello CE, Nunes EP, Sousa PS, 
Rodrigues LL, et al. Prevalence of baseline NS3 resistance-
associated substitutions (RASs) on treatment with protease 
inhibitors in patients infected with HCV genotype 1. Clin Res 
Hepatol Gastroenterol. 2019;43:700-6. 
 18.  Cheinquer H, Sette Jr H, Wolff FH, Araujo A, Coelho-Borges S, 
Soares SR, et al. Treatment of chronic HCV infection with the 
new direct acting antivirals (DAA): first report of a real-world 
experience in Southern Brazil. Ann Hepatol. 2017;16:727-33. 
 19.  Mucenic M, Brandao AB, Marroni CA, Medeiros Fleck Jr A, 
Zanotelli ML, Kiss G, et al. Daclatasvir and Sofosbuvir with or 
without Ribavirin in liver transplant recipients: a single-center 
real-world study. Transplant Proc. 2018;50:769-71. 
 20.  Araujo A, Valenzuela-Granados V, Lopes AB, Michalczuk MT, 
Mantovani A, Alvares-da-Silva MR. Sofosbuvir-based antiviral 
therapy in patients with recurrent HCV infection after liver 
transplant : a real-life experience. Ann Hepatol. 2019;18:450-5. 
 21.  Zanaga LP, Santos AG, Ataíde EC, Boin IF, Stucchi RS. Recurrent 
hepatitis C treatment with direct-acting antivirals: a real-life 
study at a Brazilian liver transplant centre. Braz J Med Biol 
Res. 2019;52:e8519. 
 22.  Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation 
of the Abbott RealTime HCV assay for quantitative detection 
of hepatitis C virus RNA. J Clin Virol. 2007;38:96-100. 
 23.  Kesli R. An overview of the laboratory assay systems and reactives 
used in the diagnosis of Hepatitis C virus (HCV) infections. 
In: Abuelzein E, editor. Trends in immunolabelled and related 
techniques. Rijeka: InTech; 2012. p. 340-9. 
 24.  Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner 
J, et al. Development of a simple noninvasive index to predict 
significant fibrosis in patients with HIV/HCV coinfection. 
Hepatology. 2006;43:1317-25. 
 25.  The French METAVIR Cooperative Study Group. Intraobserver 
and interobserver variations in liver biopsy interpretation in 
patients with chronic hepatitis C. Hepatology. 1994;20:15-20
 26.  Wai C, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, 
Conjeevaram HS, et al. A simple noninvasive index can predict 
both significant fibrosis and cirrhosis in patients with chronic 
hepatitis C. Hepatology. 2003;38:518-26.
 27. Brasil. Secretaria deVigilância em Saúde, Departamento de 
Vigilância, Prevenção e Controle das Infecções Sexualmente 
Transmissíveis, do HIV/Aids e das Hepatites Virais. Protocolo 
clínico e diretrizes terapêuticas para hepatite C e coinfecções. 
Brasília; Ministério da Saude; 2019. 
 28.  Coilly A, Fougerou-Leurent C, de Ledinghen V, Houssel-Debry 
P, Duvoux C, Di Martino V, et al. Multicentre experience using 
daclatasvir and sofosbuvir to treat hepatitis C recurrence: the 
ANRS CUPILT study. J Hepatol. 2016;65:711-8. 
 29.  Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, 
Yang R, et al. Daclatasvir with Sofosbuvir and Ribavirin for 
Hepatitis C virus infection with advanced cirrhosis or post-liver 
transplantation recurrence. Hepatology. 2016;63:1493-505. 
 30.  Gutierrez JA, Carrion AF, Avalos D, O’Brien C, Bhamidimarri 
KR, Peyton A. Sofosbuvir and Simeprevir for treatment of 
hepatitis C virus infection in liver transplant recipients. Liver 
Transpl. 2015;21:823-30. 
 31.  Pungpapong S, Aqel B, Leise M, Werner KT, Murphy JL, 
Henry TM, et al. Multicenter experience using Simeprevir 
and Sofosbuvir with or without Ribavirin to treat Hepatitis C 
genotype 1 after liver transplant. Hepatology. 2015;61:1880-6. 
 32.  Liu J, Ma B, Cao W, Li M, Bramer WM, Peppelenbosch MP, et al. 
Direct-acting antiviral agents for liver transplant recipients with 
recurrent genotype 1 hepatitis C virus infection: systematic 
review and meta-analysis. Transpl Infect Dis. 2019;21:e13047. 
 33.  Lobato CM, Codes L, Silva GF, Souza AF, Coelho HS, Pedroso 
ML, et al. Direct antiviral therapy for the treatment of hepatitis 
C: a real-world study from Brazil. Ann Hepatol. 2019;18:849-
54. 
 34.  Singh S, Facciorusso A, Loomba R, Falck-Ytter YT. Magnitude 
and kinetics of decrease in liver stiffness after anti-viral therapy 
in patients with chronic Hepatitis C: a systematic review 
and meta-analysis Siddharth. Clin Gastroenterol Hepatol. 
2018;16:27-38. 
Silva et al.
Rev Inst Med Trop São Paulo. 2021;63:e6Page 10 of 10
 35.  Omar H, Said M, Eletreby R, Mehrez M, Bassam M, Abdellatif Z, 
et al. Longitudinal assessment of hepatic fibrosis in responders 
to direct-acting antivirals for recurrent hepatitis C after liver 
transplantation using noninvasive methods. Clin Transplant. 
2018;32:e13334. 
 36.  Hsu WF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, et al. 
Rapid decline of noninvasive fibrosis index values in patients 
with hepatitis C receiving treatment with direct-acting antiviral 
agents. BMC Gastroenterol. 2019;19:63. 
 37.  Elfeki MA, Mrad RA, Esfeh JM, Zein NN, Eghtesad B, Zervos X, 
et al. Sofosbuvir/Ledipasvir without Ribavirin achieved high 
sustained virologic response for hepatitis C recurrence after 
liver transplantation: two-center experience. Transplantion. 
2017;101:996-1000. 
 38.  Nogueras López F, López Garrido A, Ortega Suazo EJ, Vadillo 
Calles F, Valverde López F, Espinosa Aguilar MD. Therapy 
with direct-acting antiviral agents for hepatitis C in liver 
transplant recipients. Transplant Proc. 2018;50:631-3. 
 39.  Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, et al. 
Assessing patient preferences for treatment decisions for new 
direct-acting antiviral (DAA) therapies for chronic hepatitis C 
virus infections. Adv Ther. 2019;36:2475-86. 
 40.  Bernuth S, Grimm D, Vollmar J, Darstein F, Mittler J, Heise M, 
et al. Efficacy and safety of direct-acting antiviral therapy in 
previous hard-to-treat patients with recurrent hepatitis C virus 
infection after liver transplantation: a real-world cohort. Drug 
Des Devel Ther. 2017;11:2131-8. 
